Mucosolvan 24 Hours

Quick links

Choose a section

Quick links to important sections

Advertisements

Mucosolvan 24 Hours

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Mucosolvan 24 Hours

Quick Facts: Mucosolvan 24 Hours

Property Description
Active Ingredient Ambroxol Hydrochloride (HCl)
Form Sustained-Release Capsule (Oral)
Pharmacological Class Mucolytic and Secretolytic Agent
Common Use Symptomatic relief of thickened respiratory mucus
Origin Synthetic Compound (Metabolite of Bromohexine)

What Type of Medicine is Mucosolvan 24 Hours?

Mucosolvan 24 Hours is a single-ingredient pharmacological preparation classified as a mucolytic agent and secretolytic agent, which is a type of expectorant. The active substance is Ambroxol Hydrochloride (HCl), the International Nonproprietary Name (INN). Ambroxol is a synthetic compound and the active metabolite of Bromohexine, a lineage that has been clinically recognized for supporting respiratory health for decades. This classification confirms its fundamental role in the management of conditions characterized by the excessive or abnormal presence of thick, viscid mucus.

The 24-Hour Sustained-Release Capsule Formulation

The specific pharmaceutical form of this product is an oral Sustained-Release Capsule, also referred to as an Extended-Release Capsule. The designation "24-Hours" signifies that the capsule's specialized formulation is engineered to provide a controlled and gradual release of the Ambroxol HCl into the system. This sustained-release delivery is designed to maintain a consistent therapeutic concentration of the mucolytic agent continuously, allowing for a simplified once-daily dosing schedule, which is often preferred for long-term adherence.

General Purpose: Clearing the Airways

The essential therapeutic purpose of this medication is to facilitate the effective expulsion of phlegm by modifying the quality of respiratory secretions. Ambroxol HCl works to reduce the viscosity and stickiness of sputum, a mechanism known as secretolysis. A review of the substance’s action confirms that it is widely used to assist the body's natural defense mechanism, mucociliary clearance, in the removal of secretions. By targeting and thinning the mucus, the drug supports the body's ability to clear retained secretions and contributes to easier breathing, particularly in scenarios involving heavy, difficult-to-clear mucus production.

Advertisements

What side effects are possible with Mucosolvan 24 Hours?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Ambroxol Hydrochloride as classified in official government regulatory documents.


Adverse Reaction Frequencies

The safety profile is formally organized by frequency, with the majority of events related to the gastrointestinal system and sensory changes. Common (ge1/100 to <1/10) effects listed include nausea, diarrhoea, and sensory alterations such as dysgeusia (changed taste) and oral or pharyngeal hypoesthesia (numbness in the mouth or throat). Uncommon (ge1/1000 to <1/100) reactions include vomiting, abdominal pain, dyspepsia, and dry mouth. Rare effects include hypersensitivity reactions, rash, and urticaria.


Serious Adverse Reactions and Safety Constraints

Official labeling documents a risk of rare but serious reactions classified as Not Known frequency, including anaphylactic reactions (e.g., anaphylactic shock, angioedema) and Severe Cutaneous Adverse Reactions (SCARs), which encompass conditions like Stevens-Johnson Syndrome (SJS). The medicine is contraindicated in individuals with known hypersensitivity to Ambroxol. Caution is necessary when used in patients with compromised airways motility or a history of peptic or duodenal ulcers.


Population-Specific Safety Notes

Specific regulatory caution applies to certain populations. The medicine is not recommended during the first trimester of pregnancy and during breastfeeding. Furthermore, caution is advised for patients with severe hepatic or renal impairment due to the potential for the accumulation of metabolites, which is a key regulatory safety consideration in these patient groups.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented information regarding an overdose of Ambroxol Hydrochloride (Mucosolvan 24 Hours), based strictly on government regulatory documents.


Overdose Scope

Element Official Regulatory Statement
Documented overdose presentations Symptoms are reported as an extension of the medicine's known undesirable effects, including diarrhea, nausea, vomiting, dyspepsia, heartburn, and short-term restlessness.
Physiological systems affected (as stated in label) Based on preclinical data for extreme overdosage, potential severe effects may involve the circulatory system, specifically resulting in hypotension (low blood pressure).
Dose-related or exposure-related factors (if applicable) Severe outcomes and specific management procedures are referenced in the context of extreme or very high overdosage levels.
Population-specific overdose notes (if applicable) No specific overdose manifestations or required actions are explicitly listed for any population group in the official overdose sections.
Emergency-response statements (as written in official documents) Management should be symptomatic and supportive in nature; procedures like gastric lavage should be considered only in cases of very high overdose.
When immediate medical help is required (label-derived phrasing only) The patient must consult a doctor or seek emergency medical treatment upon taking a dose greater than recommended.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents) Symptoms are primarily categorized as an exacerbation of common undesirable effects; severe outcomes are associated with extreme overdosage levels.
Regulatory basis (EMA / FDA / etc.) Information is drawn from official Summary of Product Characteristics (SmPC) and equivalent national drug authority prescribing information.
Overdose-context constraints (as defined in official documents) No specific antidote is known or reported for Ambroxol Hydrochloride.

Resulting Overdose Structure

Official overdose statements:

  • Overdose typically presents as an increase in common gastrointestinal effects like nausea and vomiting.
  • Official regulatory information explicitly states that there is no specific antidote for Ambroxol.
  • Treatment for overdose is defined as symptomatic and supportive management.
  • The patient is required to seek emergency medical treatment or consult a doctor when the recommended dose has been exceeded.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the overdose profile by establishing that the manifestations are chiefly an extension of known symptoms, and management is entirely supportive due to the absence of a specific antidote. This framework mandates that patients seek immediate medical attention or consult a doctor whenever an excess dose is ingested, ensuring professional oversight for potential symptom escalation or necessary supportive procedures.

Advertisements

Therapeutic Uses of Mucosolvan 24 Hours

The primary therapeutic role of Mucosolvan 24 Hours (Ambroxol HCl) is to provide symptomatic relief in conditions presenting with abnormal respiratory secretions. Ambroxol is applied across domains where additional symptomatic support is needed.

This medication is commonly used across conditions characterized by the production of thick, sticky (viscid) phlegm and the resulting symptoms that interfere with daily functioning. It is relevant for easing symptoms associated with Acute Bronchitis, as well as the chronic burden of heavy mucus in conditions like Chronic Bronchitis and COPD.

Managing Conditions with Thick, Tenacious Mucus

This medicine is applied in settings where symptoms cluster into patterns requiring supportive management, specifically relating to difficult expectoration. The sustained-release formula assists with managing symptoms related to persistent, thick secretions, which contributes to easing the overall symptom burden across the day. During acute flare-ups, it is used to provide symptomatic relief that may help patients cope more steadily with episodes of heightened respiratory distress caused by retained, sticky secretions. The medication helps manage symptoms linked to the production of thick secretions, supporting an easier and less strenuous experience of the productive (chesty) cough.


Quick Fact: Relief for Difficult Expectoration

  • Target Symptoms: Thick, viscid phlegm and unproductive, strenuous cough.
  • Therapeutic Goal: To ease the symptom load associated with difficult expectoration in acute and chronic conditions.
Advertisements

Eligibility and Restrictions for Use

Mucosolvan 24 Hours (Ambroxol Hydrochloride sustained-release capsule) is subject to specific population eligibility rules defined by regulatory authorities.

Contraindicated Populations

Use is strictly prohibited for individuals with known hypersensitivity to the active ingredient, Ambroxol Hydrochloride, or to any of the excipients in the sustained-release capsule. Additionally, patients with rare hereditary problems of fructose intolerance are formally contraindicated.

Age and Physiological Restrictions

The sustained-release formulation is intended for use by adults and adolescents who are ge 12 years of age. It is officially not recommended for children under 12 due to the high dosage contained within the capsule. Furthermore, use is not recommended during the first trimester of pregnancy and while breastfeeding, as the active substance is known to be excreted into breast milk.

Conditional Use and Impairment

Conditional use is required for populations with specific pre-existing conditions. Patients with severe hepatic impairment or severe renal impairment must use the medicine only under medical supervision, which typically necessitates an adjustment to the dose or the dosing interval. Caution is also advised for individuals with impaired bronchial motility or a history of peptic ulcer disease.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ambroxol Hydrochloride, the active ingredient in Mucosolvan 24 Hours, describes specific interaction patterns related to pharmacodynamics and pharmacokinetics, primarily involving certain medicines and patient physiological conditions.

Documented Drug-Drug Interactions

Classification Interacting Substances Official Outcome / Restriction
Pharmacodynamic Risk Cough Suppressants (Antitussives) Co-administration is not recommended due to the potential for an impaired cough reflex, which may lead to the dangerous accumulation of sputum and subsequent airway obstruction.
Exposure Modification Antibiotics (e.g., Amoxicillin, Erythromycin, Cefuroxime, Doxycycline) Co-administration is documented to lead to an increase of antibiotic concentrations in bronchial secretions and lung tissue.

Other Interactions and Constraints

While no other clinically relevant unfavorable interactions with medications or food have been formally reported, specific population constraints are noted in regulatory documents.

Constraint Type Condition Official Caution Statement
Pharmacokinetic Clearance Severe Renal Impairment or Serious Hepatic Impairment Caution is required, as a reduced clearance is expected, which may lead to the accumulation of hepatic metabolites of ambroxol in the body.

Overall, regulatory documentation states that no clinically significant adverse drug interactions have been observed with medications other than the noted examples. This information is derived exclusively from governmental regulatory labels.

Advertisements

Mechanism of Action

Modulation of Secretion Quality and Transport

This domain centers on the secretagogue action of the molecule, which modulates specialized cells (Type II Pneumocytes) to enhance the release of pulmonary surfactant. The integration of surfactant into the secretions reduces their surface tension and adhesiveness, resulting in a change in the physical properties (rheology) of the mucus, which supports mucociliary transport.


Interaction with Airway Sensory Signaling

The molecule exerts a local physiological effect by inhibiting specific voltage-gated sodium ion channels (Nav channels) found on sensory nerve endings (C-fibers) in the respiratory tract. By blocking the rapid transmission of electrical impulses along these fibers, the mechanism alters the initiation and propagation of sensory signals originating in the bronchial lining.


Action on Cellular Oxidative and Inflammatory Pathways

A supplementary mechanism involves the molecule's antioxidant properties, where it acts as a scavenger of free radicals, and its action in modulating the release of certain pro-inflammatory mediators. This activity results in the neutralization of free radicals and the altered release of pro-inflammatory mediators within the bronchial mucosa.

Advertisements

Dosage and Administration Information

How to Use Mucosolvan 24 Hours — Official Administration Guidelines

The administration of Mucosolvan 24 Hours (Ambroxol Hydrochloride 75 mg Sustained-Release Capsule) is dictated by its specialized formulation, which controls the release of the active substance over a full day. The medicine is intended for oral administration and is administered according to a single, fixed daily regimen.

Administration Scope

Parameter Official Instruction
Route of administration Oral administration only.
Dosing schedule The standard dose is one 75 mg SR capsule.
Frequency pattern Once daily (OD), facilitated by the sustained-release mechanism.
Age-group administration Typically intended for adults and adolescents over 12 years of age.

Procedural and Contextual Requirements

Official instructions establish specific constraints for taking the sustained-release capsule to ensure correct absorption:

  1. The 75 mg capsule must be swallowed whole and should not be crushed, chewed, or opened.
  2. The capsule is generally instructed to be taken after a meal (postprandially) and consumed with adequate fluid.

Special Conditions: In cases of severe renal or serious hepatic impairment, official labeling advises caution. The use of the drug in these scenarios may require the administration of lower doses or an extension of the time interval between doses due to the potential for metabolite accumulation.

Advertisements

Recent Clinical Evidence

Evidence for Acute Respiratory Symptom Relief

Research examining the active ingredient in Mucosolvan 24 Hours, ambroxol hydrochloride, focuses on short-term Randomized Controlled Trials (RCTs) for conditions involving periods of heightened symptoms, such as Lower Respiratory Tract Infections (LRTI). Studies monitor patient-reported discomfort, cough severity, and sputum characteristics. A key limitation is that evidence often derived from immediate-release formulations, making its full applicability to the 24-hour sustained-release capsule uncertain.


Evidence in Chronic Respiratory Conditions

For Chronic Bronchitis and COPD, research explores outcomes over long periods (months to years), including the frequency of acute exacerbations and changes in lung function (e.g., FEV1). Findings were mixed across the general population, with more patterns observed in symptomatic subgroups. Evidence quality varies across these long-term studies.


Long-Term Studies and Follow-Up Duration

Long-term follow-up spans up to 2 years to assess the monitoring of recurring respiratory episodes. Data are still emerging regarding outcomes over many years, and long-term effects are not fully established.


Evidence in Special Populations

Research has been studied for in pediatric patients (children), often utilizing alternative oral formulations, and in older adults with chronic conditions. It is noted that the results apply only to the populations studied, and data for complex patient groups remain insufficient.


What Remains Uncertain About the Research Base

Comparative evidence is lacking for many clinical endpoints when testing the sustained-release capsule directly against older immediate-release products. Overall certainty remains low for very long-term outcomes, and subgroup findings are uncertain or require more replication.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Mucosolvan 24 Hours (FAQ)


Q: Can Mucosolvan 24 Hours be taken with antibiotics?

A: Official regulatory documents indicate that co-administration with certain antibiotics (such as amoxicillin, erythromycin, and cefuroxime) is associated with a change in how the antibiotics are distributed. This is documented to increase the concentration of the antibiotic within the bronchial secretions and lung tissue, which is a pharmacokinetic interaction.


Q: Is it okay to take Mucosolvan 24 Hours if I have high blood pressure?

A: High blood pressure (hypertension) is not listed among the official contraindications or special warnings that require specific caution in the regulatory documents for this single-ingredient product. Contraindications are generally reserved for conditions such as known hypersensitivity to the drug.


Q: Can I use Mucosolvan 24 Hours if I have asthma or COPD?

A: The medicine is indicated for use in chronic respiratory conditions associated with impaired mucus transport. Regulatory documents indicate that caution is advised for use in patients with impaired bronchial motility, a condition that may be present in some chronic respiratory diseases.


Q: Can I take Mucosolvan 24 Hours if I have a stomach ulcer?

A: Official labeling advises that caution should be exercised when the medicine is used by patients who have a history of, or currently have, peptic or duodenal ulceration. This conditional use is a point of consideration noted in the regulatory documents.


Q: Why do some people say they felt 'jittery' after taking it?

A: The active ingredient's official side effect profile lists common gastrointestinal effects like nausea and vomiting. While not commonly reported, official documents note that some users report agitation of indeterminate frequency, which may relate to the perception of feeling 'jittery'.


Q: Can I take it if I have liver disease?

A: Official labeling advises that caution is required in patients with severe hepatic (liver) impairment due to the potential for the accumulation of metabolites. Regulatory documents state that use in these scenarios may necessitate an adjustment to the dose or the time interval between doses.


Q: Do studies support the long-acting claim of Mucosolvan 24 Hours?

A: Regulatory documents confirm that this is a sustained-release formulation intended for once-daily dosing. The product’s design is based on pharmacokinetics (how the body handles the drug) showing a gradual release to maintain a consistent therapeutic concentration over 24 hours.


Q: Is the '24 Hours' dosage the same in all countries?

A: The sustained-release formulation is internationally standardized across major markets. The dosage for adults and adolescents over 12 years of age is consistently defined in regulatory documents as one 75 mg SR capsule once daily.


Q: Can I take Mucosolvan 24 Hours if I have kidney problems?

A: Official labeling advises that caution is required in patients with severe renal (kidney) impairment due to the potential for the accumulation of metabolites. Regulatory documents state that use in these scenarios may necessitate an adjustment to the dose or the time interval between doses.


Q: Is Mucosolvan 24 Hours supposed to make me cough more at first?

A: The official mechanism of action involves stimulating mucociliary activity, which helps to loosen and thin secretions. This process supports the clearing of phlegm, which is the intended therapeutic effect.


Q: How long does it typically take for Mucosolvan 24 Hours to start working?

A: Official documentation for the active ingredient suggests an onset of action typically occurs within the first hour of oral administration. The onset for the sustained-release capsule is gradual due to its specialized design, which is intended to maintain a therapeutic effect for a full 24 hours.


Q: Does Mucosolvan 24 Hours contain codeine or any narcotic ingredients?

A: No. The active ingredient in Mucosolvan 24 Hours is Ambroxol Hydrochloride, which is classified as a synthetic mucolytic agent. Codeine is an opioid cough suppressant and is not listed as an ingredient in this product.


Q: Are there any common foods or drinks that interact with Mucosolvan 24 Hours?

A: Official regulatory documentation states that no clinically significant adverse interactions between the active ingredient and food have been formally reported, other than specific drug-drug interactions. The capsule is generally instructed to be taken with adequate fluid.


Q: What happens if I accidentally miss a dose of Mucosolvan 24 Hours?

A: Patient information guidelines commonly advise that if a dose is missed, it should be taken as soon as the patient remembers, unless it is almost time for the next scheduled dose. Patient information guidelines indicate that a double dose should not be taken to compensate for a missed dose.


Q: Does Mucosolvan 24 Hours cause drowsiness or affect driving?

A: Studies on the ability to drive and use machines have not been formally performed for this medicine. However, official documents note that the active ingredient may rarely cause side effects such as drowsiness or dizziness, and official information indicates that caution may be necessary.


Q: What is the main difference between Mucosolvan 24 Hours and a generic ambroxol product?

A: The main difference lies in the formulation. Mucosolvan 24 Hours is a sustained-release (SR) capsule, specifically designed to release the active substance slowly over 24 hours for once-daily dosing. Many generic ambroxol products are immediate-release (IR) formulations that may require more frequent dosing.


Q: Does Mucosolvan 24 Hours contain gluten or lactose?

A: The active ingredient, Ambroxol Hydrochloride, is not derived from gluten-containing sources. While the capsule typically does not contain lactose, a specific warning is listed for patients with rare hereditary problems of fructose intolerance. Patients should always review the specific excipient list.


Q: Can this medication affect my blood sugar levels?

A: Ambroxol Hydrochloride, as a single agent, is not generally known to affect blood sugar levels. Official labeling does not list diabetes as a specific contraindication or warning that requires dose monitoring.


Q: What should I do if my symptoms don't improve after a few days on Mucosolvan 24 Hours?

A: Patient information guidelines generally state that the drug should not be taken for more than 4 to 5 days without consulting a health professional. If symptoms worsen or do not improve within this standard self-treatment timeframe, patient information guidelines indicate that further consultation may be appropriate.


Q: Does Mucosolvan 24 Hours help with nasal congestion as well as cough?

A: The official therapeutic indication for this product is limited to the treatment of bronchopulmonary diseases associated with abnormal mucus secretion and transport in the lower airways. Nasal congestion, which involves the upper airways, is not listed as an indication.


Q: Why is this medication only available as a once-daily tablet?

A: This product is a sustained-release (SR) capsule. This specialized pharmaceutical design allows the active ingredient to be gradually released into the body over a full 24-hour period, which enables the simplified once-daily dosing schedule.


Q: Is Mucosolvan 24 Hours safe for elderly patients?

A: Official regulatory data indicate that age does not have a significant effect on how the body processes the active ingredient. Therefore, a dose adjustment is not necessary for the geriatric population based on age alone, although the standard cautions for severe organ impairment still apply.


Q: Can I drink alcohol while taking Mucosolvan 24 Hours?

A: Official regulatory documents do not report any specific, clinically significant interactions between the single-ingredient product (Ambroxol Hydrochloride) and alcohol. However, some liquid forms of the active ingredient may contain alcohol as an excipient.


Q: Can Mucosolvan 24 Hours be used for a dry cough?

A: The drug's mechanism and therapeutic indication are specifically aimed at treating conditions involving abnormal, thick, or viscous mucus secretion (a productive or 'wet' cough). It is not officially indicated for the treatment of a dry, non-productive cough, which lacks phlegm.


Q: Does Mucosolvan 24 Hours affect the effectiveness of oral contraceptives?

A: Official regulatory documentation states that no clinically significant adverse interactions have been observed between the active ingredient (Ambroxol Hydrochloride) and other medications, and this includes oral contraceptives.


Q: Is there a liquid or syrup version of Mucosolvan 24 Hours?

A: The Mucosolvan 24 Hours product line refers specifically to the sustained-release capsule (75 mg). While other non-24 hour formulations containing the same active ingredient (Ambroxol Hydrochloride) are available globally, they are not marketed under the 24-hour designation.


Q: Does Mucosolvan 24 Hours contain any sugar?

A: The sustained-release capsule does not typically contain sucrose (table sugar), but a specific warning is listed for patients with rare hereditary problems of fructose intolerance. This indicates that patients should review the specific excipient list for the formulation being used.


Q: Why might a doctor recommend Mucosolvan 24 Hours for a chronic condition?

A: The medication is officially indicated for the secretolytic therapy of chronic bronchopulmonary diseases associated with abnormal mucus secretion. The 24-hour formulation is often utilized for chronic management because its sustained release simplifies long-term adherence by allowing for a convenient once-daily dose.

Advertisements

How should Mucosolvan 24 Hours be stored and disposed of?

Storage and Disposal Requirements

All storage and disposal procedures for Mucosolvan 24 Hours (ambroxol hydrochloride 75 mg sustained-release capsules) are strictly defined by regulatory authorities to ensure product stability and environmental safety.

Storage Condition Requirement
Temperature Limit Store not exceeding 30 C.
Environmental Protection Must be stored in a dry place and protected from direct light exposure.
Child Safety Keep out of the sight and reach of children.

Official Disposal Rules

Expiration and disposal must follow regulatory guidance. The product must not be used after the expiry date shown on the package. Do not dispose of unused or expired medicine via wastewater (e.g., in the sink or toilet). Disposal must be carried out in accordance with local regulations, often requiring submission to a pharmacist or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mucosolvan 24 Hours found in:

A-Z Index: